Ironwood Pharmaceuticals (IRWD)
(Real Time Quote from BATS)
$4.06 USD
-0.02 (-0.49%)
Updated Sep 24, 2024 01:12 PM ET
5-Strong Sell of 5 5
C Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Ironwood Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 443 | 411 | 414 | 390 | 428 |
Cost Of Goods | 0 | 0 | 0 | 3 | 24 |
Gross Profit | 443 | 411 | 414 | 386 | 405 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,388 | 160 | 182 | 243 | 284 |
Income After Depreciation & Amortization | -945 | 250 | 232 | 143 | 120 |
Non-Operating Income | 19 | 10 | 0 | -5 | -25 |
Interest Expense | 22 | 8 | 31 | 29 | 37 |
Pretax Income | -948 | 252 | 201 | 109 | 59 |
Income Taxes | 83 | 77 | -328 | 3 | 0 |
Minority Interest | -29 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -1,032 | 175 | 528 | 106 | 59 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -37 |
Net Income (GAAP) | -1,002 | 175 | 528 | 106 | 22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -944 | 252 | 234 | 147 | 126 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 2 | 4 | 6 |
Income After Depreciation & Amortization | -945 | 250 | 232 | 143 | 120 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 155.44 | 186.31 | 164.42 | 160.66 | 153.61 |
Diluted EPS Before Non-Recurring Items | -6.27 | 0.96 | 1.16 | 0.79 | 0.55 |
Diluted Net EPS (GAAP) | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 |
Fiscal Year end for Ironwood Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 94.40 | 74.88 | 117.55 | 113.74 | 107.38 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 94.40 | 74.88 | 117.55 | 113.74 | 107.38 |
SG&A, R&D, and Dept/Amort Expenses | 69.42 | 63.86 | 79.97 | 73.72 | 1,190.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 24.98 | 11.02 | 37.58 | 40.02 | -1,083.15 |
Non-Operating Income | 1.37 | 1.17 | 1.19 | 1.75 | 8.76 |
Interest Expense | 7.47 | 7.23 | 8.42 | 9.84 | 1.84 |
Pretax Income | 18.88 | 4.96 | 30.36 | 31.93 | -1,076.22 |
Income Taxes | 19.74 | 9.12 | 32.11 | 17.98 | 13.26 |
Minority Interest | 0.00 | 0.00 | -0.66 | -1.37 | -27.29 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.86 | -4.16 | -1.74 | 13.95 | -1,089.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -0.86 | -4.16 | -1.09 | 15.32 | -1,062.19 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 159.01 | 157.70 | 156.01 | 186.89 | 155.37 |
Diluted EPS Before Non-Recurring Items | 0.00 | -0.02 | 0.00 | 0.12 | 0.31 |
Diluted Net EPS (GAAP) | -0.01 | -0.03 | 0.05 | 0.09 | -6.84 |